Expanding Sleep And Rare Disease Markets Will Unlock Future Potential

Shared on30 Apr 25
Fair value Decreased 6.14%

Shared on23 Apr 25
Fair value Increased 8.35%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 7.91%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.43%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Increased 0.14%

AnalystConsensusTarget has decreased revenue growth from 22.1% to 18.1% and increased future PE multiple from 10.5x to 11.6x.